Infliximab als Reservtherapie bei Patienten mit schwerer tacrolimus-refraktärer Colitis ulcerosa/indeterminata
DN Barthel(Robert Bosch Hospital), K Herrlinger(Robert Bosch Hospital), EF Stange(Robert Bosch Hospital), Jürgen Büning(University Hospital Schleswig-Holstein), C.-C. Barthel(Robert Bosch Hospital), KJ Schmidt(Universitäres Kinderwunschzentrum Lübeck), Jan Wehkamp(Robert Bosch Hospital), Klaus Fellermann(Apple (Israel))
Cited by 0
Related Papers
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566